BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
Go back to BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia| (NASDAQ: BBIO) | Delayed: 67.74 +0.19 (0.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $67.55 | 52 Week High | $ | |||
| Open | $68.04 | 52 Week Low | $ | |||
| Day High | $68.79 | P/E | N/A | |||
| Day Low | $67.55 | EPS | $ | |||
| Volume | 3,036,099 | |||||



